Mizuho Securities USA LLC Raises Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Mizuho Securities USA LLC lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 45.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,761 shares of the company’s stock after purchasing an additional 2,424 shares during the quarter. Mizuho Securities USA LLC’s holdings in IDEXX Laboratories were worth $3,209,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of IDXX. Flossbach Von Storch SE grew its holdings in shares of IDEXX Laboratories by 5,439.3% during the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock worth $195,696,000 after purchasing an additional 464,791 shares in the last quarter. William Blair Investment Management LLC grew its holdings in shares of IDEXX Laboratories by 701.6% during the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock worth $174,527,000 after purchasing an additional 369,471 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after purchasing an additional 316,048 shares in the last quarter. Seilern Investment Management Ltd purchased a new position in shares of IDEXX Laboratories during the fourth quarter worth about $113,104,000. Finally, Vontobel Holding Ltd. grew its holdings in shares of IDEXX Laboratories by 90.1% during the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock worth $173,051,000 after purchasing an additional 198,404 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $420.99 on Monday. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a market cap of $34.12 billion, a PE ratio of 39.46, a P/E/G ratio of 3.41 and a beta of 1.39. The business has a 50 day moving average of $437.36 and a 200 day moving average of $444.76. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $548.88.

Analysts Set New Price Targets

Several analysts have issued reports on IDXX shares. Barclays upped their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Bank of America upped their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, March 15th. Finally, Leerink Partners assumed coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $533.75.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.